Sporadic BRCA1/2negative | Familial BRCA1/2negative | BRCA1 index | BRCA1 negative phenocopies* | BRCA2 index | |
Number | 113 | 756 | 126 | 15 | 106 |
Median age | 32 | 46 | 40 | 56 | 43 |
Lobular | 7/113 (4%) | 80/756 (11%) | 2/126 (2%) | 3/15 (20%) | 3/106 (3%) |
LCIS | 1/113 (1%) | 11/756 (1.5%) | 0/126 | 0/15 | 0/106 |
DCIS | 9/113 (8%) | 65/756 (9%) | 5/126 (4%) | 1/15 (7%) | 6/106 (6%) |
Mucinous | 1/113 (1%) | 2/756 | 1/126 | 1/15(7%) | 0/106 |
Grade 1 IDC | 5/95 (6%) | 111/598 (18%) | 3/117 (3%) | 1/10 (10%) | 3/97 (3%) |
Grade 2 IDC | 20/95 (21%) | 249/598 (43%) | 19/117 (16%) | 5/10 (50%) | 42/97 (44%) |
Grade 3 IDC | 70/95 (73%) | 238/598 (39%) | 96/117 (82%) | 4/10 (40%) | 52/97 (53%) |
Her2 +ve | 7/40 (17%) | 52/169 (31%) | 0/51 (0%) | 1/5 (20%) | 2/22 (9%) |
ER +ve | 30/66 (45%) | 373/463 (81%) | 22/87 (24%) | 8/11 (73%) | 65/80 (78%) |
ER −ve | 36/66 (55%) | 90/463 (19%) | 65/87 (76%) | 3/11 (27%) | 15/80 (22%) |
Grade 3 triple −ve | 20/66 (30%) | 34/463 (7%) | 51/87 (63%) | 1/11 (9%) | 9/80 (11%) |
Grade 3 ER −ve, no Her2 status | 9/66 (13%) | 19/463 (4%) | 7/87 (9%) | 3/11 (25%) | 2/80 (3%) |
Grade 3 ER −ve, Her2 +ve | 4/26 (15%) | 12/43 (28%) | 0/51 (0%) | 1/12 (8%) | 1/9 (11%) |
Assumed† grade 3 triple −ve | 28/95 (30%) | 48/463 (10%) | 58/87 (67%) | 2/10 (20%) | 11/80 (14%) |
*Women testing negative for the family BRCA1 mutation with breast cancer.
†This is assumed on the basis that untested grade 3 ER-negative tumours have the same ratio as those tested for Her2.
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; IDC, invasive ductal carcinoma; LCIS, lobular carcinoma in situ.